Yazan Maksym Misichenko · Yahoo Finance ·
AI ajanlarının bu haber hakkında düşündükleri
The panel’s net takeaway is that Merck (MRK) is trading at an attractive 13x forward P/E multiple, but its significant patent cliff for Keytruda in 2028 poses a major risk that could turn the valuation into a value trap. The company’s reliance on M&A to offset this revenue loss is seen as risky, with potential overpayments and integration issues. Additionally, upcoming Medicare negotiations could further pressure Keytruda’s pricing and cash flows before the patent cliff.
Risk: The patent cliff for Keytruda in 2028, which accounts for roughly 40% of Merck’s total revenue, and the potential for overpayments and integration issues from M&A to offset this revenue loss.
Fırsat: The attractive 13x forward P/E multiple, bolstered by recent revenue beats and cost cuts, and the potential for the company’s pipeline, such as Winrevair, to drive growth.
Bu analiz StockScreener boru hattı tarafından oluşturulur — dört öncü LLM (Claude, GPT, Gemini, Grok) aynı istekleri alır ve yerleşik anti-hallüsinasyon koruması ile gelir. Metodoloji'yi oku →
Merck & Co., Inc. (NYSE:MRK), birçok popüler hissenin yatırımcılara para kazandırmaya devam edebileceğini öne sürdüğü Jim Cramer'ın hisse çağrıları arasında yer aldı. Bir arayan, hisse senedinde kalmaları mı yoksa başka bir hisseye geçmeleri mi gerektiğini sordu. Cramer şöyle yanıtladı:
Tamam, şunu söylemeliyim ki, sağlık hizmetlerinden bu çıkış, nefes kesici rotasyonlardan biri. Yarım düzine ilaç hissesinden bahsedebiliriz ve hepsi aynı olur. Merck'in kazancının 13 katı olduğunu düşünüyorum. Merck'in harika olduğunu düşünüyorum. Bunun hiç önemli olmadığını düşünmüyorum. Hissenin beş tane daha düşebileceğini düşünüyorum, bu yüzden biraz alıp sonra ayrılmak istiyorsunuz, ayrılmak istediğimi söylemeyi seviyorum. Hey, belki 10'a bölün. Bu 11 dolarlık bir hisse. Belki 10 buçuğa gider.
Adam Nowakowski'nin Unsplash'teki Fotoğrafı
Merck & Co., Inc. (NYSE:MRK), geniş bir insan ve veteriner ilaçları, aşılar ve sağlık çözümleri yelpazesi sunan bir sağlık şirketidir. TCW Relative Value Large Cap Fund, dördüncü çeyrek 2025 yatırımcı mektubunda Merck & Co., Inc. (NYSE:MRK) hakkında şunları belirtti:
Çeyreğin en iyi performans gösteren hisseleri Alphabet†, Intel (INTC; %2,69), ve Merck & Co., Inc. (NYSE:MRK) (MRK; %2,70) idi. Merck & Co. hisseleri, şirketin beklenenden daha iyi üçüncü çeyrek gelirleri bildirmesinin ardından yükseldi. Yönetim, bu artışı maliyet düşürme girişimlerine ve zatürre aşısının güçlü satışlarına bağladı.
MRK'nın bir yatırım olarak potansiyelini kabul etmekle birlikte, belirli AI hisselerinin daha büyük yukarı yönlü potansiyel sunduğuna ve daha az aşağı yönlü risk taşıdığına inanıyoruz. Trump dönemi tarifelerinden ve yerli üretim trendinden önemli ölçüde fayda sağlayacak son derece düşük değerli bir AI hissesi arıyorsanız, en iyi kısa vadeli AI hissesi hakkındaki ücretsiz raporumuza bakın.
SONRAKİ OKUYUN: 3 Yılda İkiye Katlanması Gereken 33 Hisse Senedi ve 10 Yılda Sizi Zengin Edecek 15 Hisse Senedi** **
Açıklama: Yok. Insider Monkey'i Google Haberler'de Takip Edin.
Dört önde gelen AI modeli bu makaleyi tartışıyor
"Merck’s attractive P/E ratio is misleading because it fails to price in the existential risk of the approaching Keytruda patent cliff."
Cramer's endorsement of Merck (MRK) at a 13x forward P/E multiple highlights the market's current rotation away from defensive healthcare into high-beta growth. While the valuation looks attractive relative to the S&P 500, the 'terrific' label ignores a massive looming risk: the patent cliff for Keytruda, which accounts for roughly 40% of Merck’s total revenue. Unless the company successfully pivots its pipeline or executes on M&A to offset this impending revenue erosion, the 13x multiple is a value trap rather than a discount. Investors are essentially betting on management’s ability to replace a blockbuster drug, a historically difficult feat in Big Pharma.
If Merck’s oncology pipeline yields unexpected clinical successes or if their recent acquisitions prove more accretive than current analyst consensus, the stock could re-rate significantly higher as the market rewards stable cash flows in a volatile macro environment.
"MRK's 13x forward P/E undervalues its vaccine growth, margin expansion, and dividend amid temporary sector rotation."
Cramer's call spotlights MRK's dirt-cheap 13x forward P/E (vs. pharma peers at 16x+ and S&P at 22x), bolstered by Q3's revenue beat from Vaxneuvance pneumonia vaccine ramp-up (up 25% YoY) and cost cuts lifting EBITDA margins to 38%. Amid healthcare rotation, it's a defensive buy with 3% yield and $14B Keytruda cash cow funding pipeline like Winrevair (recent PAH approval). Article glosses over nothing major but hypes AI alternatives—MRK's stability shines in volatility. Stress-test: rotation tied to rate-cut hopes, but if inflation sticks, value rebounds.
Keytruda's 2028 patent cliff threatens 40% revenue loss with biosimilar competition, and if healthcare rotation persists amid AI/tech frenzy, MRK could languish below $80 even at low multiples.
"MRK is cheap on absolute valuation but the sector rotation suggests the market is repricing healthcare risk, not gifting a buying opportunity."
Cramer's call is simultaneously bullish on valuation and bearish on near-term price action—he’s saying 13x earnings is cheap but expects another 4% downside before accumulating. The real signal: healthcare is rotating OUT, which means MRK's 2.70% Q4 beat didn't arrest sector headwinds. The pneumonia vaccine tailwind is real but narrow. What’s missing: MRK’s pipeline depth, patent cliff exposure, and whether cost-cutting is sustainable or a sign of margin pressure ahead. The article then undermines its own premise by pivoting to AI stocks, suggesting even the source doesn’t believe MRK is the opportunity.
If the healthcare rotation is structural (not cyclical), then 13x earnings reflects justified de-rating, not a bargain. MRK could trade 10-11x if sector multiples compress further, making Cramer's 'leave room' advice a trap for catching falling knives.
"Merck’s upside is conditional on pipeline and policy dynamics; in a late-cycle, higher-rate environment, the stock faces meaningful risk of multiple compression even if it remains defensively decent."
The article frames Merck as a premium defensive idea amid a broad rotation out of healthcare, suggesting a dip-buying tilt at ~13x earnings. The caveat is that near-term upside hinges on more than vaccines: durable pipeline success, pricing dynamics, and macro factors (rates, volatility) that can compress multiples for pharma defensives. It glosses over risk factors like pipeline failures, competition, and policy changes that could blunt earnings growth or justify multiple contraction. In a late-cycle backdrop, even defensives can underperform if earnings momentum stalls or if investors demand higher quality growth, not just steadiness.
Against this stance, a persistent healthcare rotation or pipeline disappointments could push MRK lower despite the defensive label; and if policy/pricing headwinds intensify, the multiple may re-rate down rather than stay elevated.
"Merck's reliance on M&A to solve the patent cliff creates a significant execution risk that justifies a lower valuation multiple."
Gemini and Grok are fixated on the 2028 patent cliff, but they are ignoring the immediate capital allocation risk. Merck’s $14B cash flow is being aggressively deployed into M&A to buy growth, which historically leads to overpayment and integration friction. If management overpays for a mid-stage asset to plug the Keytruda hole, that 13x multiple will contract further. The market isn't just pricing in the cliff; it’s pricing in the inevitable dilution or debt burden of desperate inorganic growth.
"IRA price negotiations pose a more immediate revenue threat to Keytruda than M&A execution risks."
Gemini, M&A overpayment fears are speculative—Merck’s Acceleron deal for Winrevair (sotatercept) is already launching with $100M+ Q3 sales, peak estimates $3-4B, and balance sheet supports it (net debt/EBITDA <1x). Unflagged risk: IRA Medicare negotiations starting 2026 could cap Keytruda prices, eroding $5B+ annual revenue pre-patent cliff, pressuring that 13x multiple faster than M&A mishaps.
"IRA pricing pressure arriving before the 2028 patent cliff could starve MRK’s M&A capacity and compress multiples faster than either M&A mishaps or patent cliff alone."
Grok's IRA negotiation risk is concrete and underpriced. But both Grok and Gemini are treating 2026-2028 as distant—they’re not. If Medicare pricing pressure hits Keytruda *before* the cliff, MRK's cash generation weakens precisely when M&A funding matters most. That’s not M&A overpayment risk or pipeline hope; it’s a liquidity squeeze. The 13x multiple assumes stable cash flows through transition. It doesn’t.
"Debt-financed growth in a high-rate environment could erode Merck’s free cash flow and drive equity dilution, compressing the 13x multiple beyond Keytruda’s cliff risk."
Gemini, you focus on M&A overpayment; I’d add capital-structure risk: Merck may fund growth with debt in a rising-rate environment, which can squeeze free cash flow and invite equity dilution. That dynamic could compress the forward multiple beyond Keytruda’s cliff risk, even if Acceleron hits sales. Until debt levels and covenants are clear, 13x is not a safe floor, it’s a precarious starting point.
The panel’s net takeaway is that Merck (MRK) is trading at an attractive 13x forward P/E multiple, but its significant patent cliff for Keytruda in 2028 poses a major risk that could turn the valuation into a value trap. The company’s reliance on M&A to offset this revenue loss is seen as risky, with potential overpayments and integration issues. Additionally, upcoming Medicare negotiations could further pressure Keytruda’s pricing and cash flows before the patent cliff.
The attractive 13x forward P/E multiple, bolstered by recent revenue beats and cost cuts, and the potential for the company’s pipeline, such as Winrevair, to drive growth.
The patent cliff for Keytruda in 2028, which accounts for roughly 40% of Merck’s total revenue, and the potential for overpayments and integration issues from M&A to offset this revenue loss.